Monday, March 19, 2007

AtheroGenics continue to flog their dead horse

AtheroGenics' heart disease drug it's developing with AstraZeneca, did not meet its primary goal in a large, late-stage clinical trial.

But it will continue its development!

AtheroGenic's shares plummeted nearly 60 percent in pre-market trading while AstaZeneca's shares fell.

AZ have 45 days to decide to bail out.

More

1 comment:

Anonymous said...

They are not the only ones. look at this guys!!

http://www.ottawabusinessjournal.com/288378823795106.php

I guess management at least keep their salaries for some more months, I guess there is no plan B here.